Introduction {#s7500}
============

The 5-year overall survival rate of patients with head and neck squamous cell carcinoma (HNSCC) is about 50%, although treatment efficacy has been therapeutically improved in the last decade [@b0005], [@b0010], [@b0015]. Furthermore, the number of oropharyngeal cancers has increased worldwide over the last years [@b0020], [@b0025], [@b0030]. For patients with resected locally advanced HNSCC it has been shown in three randomized clinical trials [@b0035], [@b0040], [@b0045] that loco-regional control can be improved by postoperative radiochemotherapy (PORT-C) compared to postoperative radiotherapy (PORT) alone. However, due to their biological characteristics tumours are responding very heterogeneously to this treatment. In addition to established clinical parameters, novel biomarkers are needed to identify patient groups, which require escalated or de-escalated treatment schedules.

Independent of exogenous carcinogens, e.g. tobacco and alcohol consumption, infection with high-risk human papilloma virus (HPV) has become a major risk factor for the development of HNSCC over the past decade [@b0050]. It has been shown that patients with HPV-related HNSCC are a distinct subgroup with better outcome of primary radiochemotherapy [@b0055], [@b0060], [@b0065], [@b0070]. Recently, in a multicentre retrospective trial conducted by the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) it was shown, that patients with HPV16 DNA positive oropharyngeal tumours have a high rate of loco-regional tumour control and overall survival also after PORT-C compared to patients with HPV16 DNA negative tumours [@b0075]. Furthermore, in a recent study it was shown that high expression of previously developed tumour hypoxia-associated gene signatures [@b0080], [@b0085] and cancer stem cell (CSC) markers within the surgically removed primary tumour were associated with impaired loco-regional tumour control after PORT-C in HNSCC [@b0090]. These biomarkers were used to stratify patients with HPV16 DNA negative tumours into smaller subgroups with low and high probability of loco-regional recurrence. In order to apply this patient stratification scheme in future clinical trials regarding treatment de-escalation or intensification, these results have to be validated. Therefore, the present publication reports on the validation results of the Cox models presented in [@b0090] on HPV16 DNA status, CSC marker expression and tumour hypoxia-associated gene signatures, using an independent validation cohort of HNSCC patients treated by PORT or PORT-C.

Material and methods {#s0005}
====================

Patients {#s0010}
--------

In this publication, two patient cohorts are being considered: a training cohort previously reported by DKTK-ROG and a monocentric validation cohort. For the training cohort, inclusion criteria, data collection, handling and analyses of biomaterial were previously described in detail [@b0075], [@b0090]. Briefly, 221 patients, who received PORT-C between 2004 and 2012 at nine partner sites of the DKTK-ROG, were included to identify potential prognosticators for loco-regional control after PORT-C, such as CSCs and tumour hypoxia [@b0090]. In the retrospective validation cohort, patients treated at the Department of Radiation Oncology of the University Hospital Dresden meeting the following criteria were included: not included in the previous DKTK-ROG cohort, histologically proven squamous cell carcinoma arising from the oral cavity, oropharynx, hypopharynx or larynx; treatment between 1999 and 2006 with PORT or PORT-C in curative intention according to standard radiotherapy protocols (2 Gy/fraction, 5 fractions/week), covering the former tumour region and regional lymph nodes (50 Gy) and a boost (10--16 Gy) to the former tumour region and to the regions of involved lymph nodes. Before surgery, all patients had undergone staging (computed tomography or magnetic resonance imaging, chest X-ray and abdominal ultrasound), and only patients without evidence of distant metastases were included. Formalin-fixed paraffin-embedded (FFPE) tumour material as well as follow-up data of patients had to be available. Finally, 152 patients meeting all these criteria were included in the validation cohort. Follow-up data of patients were collected using the RadPlanBio Platform at the DKTK partner site Dresden [@b0095]. Ethical approval for retrospective analyses of clinical and biological data was obtained from the local ethics committee.

Preparation of biomaterials for biomarker analyses {#s0015}
--------------------------------------------------

FFPE blocks of the primary tumour specimens (removed by surgery) were first subjected to haematoxylin and eosin staining to histologically confirm the presence of squamous cell carcinoma. Afterwards, they were processed under standardised procedures for biomarker investigations described below.

Immunohistochemical staining of p16 and CD44 {#s0020}
--------------------------------------------

Immunohistochemical (IHC) staining of p16 was performed using the CINtec Histology kit (Roche mtm laboratories AG, Basel, CH) according to the manufacturer's instructions. Overexpression of p16 was defined as ⩾70% intense tumour staining. For p16 staining, 148 samples were evaluable. For CD44 protein expression, 145 patients of the validation cohort could be analysed. Immunohistochemical staining was performed as described in [@b0090]. CD44 staining intensity was scored (0, +, ++, +++) and tumours with a minimum of 10% staining were considered as positive. Blinded samples were scored by two independent observers (AL and CK) with an inter-observer variability of \<5%.

DNA extraction and PCR-array based analyses of HPV status {#s0025}
---------------------------------------------------------

DNA extraction and PCR-array based analyses of HPV status were performed as described previously [@b0075]. Briefly, genomic DNA was extracted from 5-μm FFPE sections using the QIAamp DNA FFPE tissue kit (Qiagen). HPV DNA analyses including genotyping were performed using the LCD-Array HPV 3.5 kit (CHIPRON GmbH, Berlin, DE) according to the instructions of the manufacturer. In total, 148 samples were evaluable for HPV DNA analyses.

nanoString RNA analyses {#s0030}
-----------------------

For the validation cohort, gene expression analyses have been performed using nanoString technology as described previously [@b0090], including two hypoxia-associated gene signatures (see [Supplementary Table 1](#s0060){ref-type="sec"}) as well as potential CSC markers *CD44*, *SLC3A2* and *MET*. Briefly, total RNA as well as reporter and capture probes specific to the genes of interest were mixed and incubated at 62 °C for 22 h. Samples were then kept at 4 °C for a maximum of 18 h and subjected to the nCounter system. Raw counts were logarithmised and then normalised to the mean of the internal level of reference genes *ACTR3*, *B2M*, *GNB2L1*, *NDFIP1*, *POLR2A*, *RPL11, RPL37A*, or to the reference genes of the corresponding hypoxia-gene signatures ([Supplementary Table 1](#s0060){ref-type="sec"}), respectively [@b0080], [@b0085]. Seven samples had to be omitted from nanoString analyses due to insufficient tumour material or due to too low RNA yield, thus 145 samples were evaluable. The *CD44* probe design, which was incorrectly designed for the training cohort [@b0090], has been corrected and included in the validation cohort.

Clinical endpoints and statistical analysis {#s0035}
-------------------------------------------

The primary endpoint was loco-regional tumour control (LRC) and secondary endpoints were freedom from distant metastases (DM) and overall survival (OS). The endpoints were calculated from the first day of radiotherapy to the date of event or censoring and survival curves were estimated by the Kaplan-Meier method. To compare patient groups stratified by HPV16 DNA status, CSC marker expression and hypoxia classification, Log-rank tests were used. For the stratification of the validation cohort with respect to CSC marker expression, the cut-offs from the training cohort reported in [@b0090] were applied. Hypoxia classification on the validation cohort was performed by k-means clustering (Euclidian distance) according to the cluster centres of the training cohort ([Supplementary Table 2](#s0060){ref-type="sec"}). The impact of potential prognostic variables on the endpoints was evaluated using univariate Cox-regression for both cohorts. To evaluate the prognostic performance of the multivariate Cox models presented in [@b0090] for the validation cohort, the concordance index (ci) was calculated, which is equal to 0.5 for non-prognostic models and equals 1 for perfectly predicting models [@b0100]. Bootstrap resampling with 10,000 samples was used to estimate the confidence intervals (CI) of the concordance index. From these bootstrap samples a *p*-value for the hypothesis ci = 0.5 was calculated. To evaluate differences between the two cohorts Mann-Whitney-*U* tests were used for continuous variables and chi-squared tests for categorical variables. The bootstrapping procedure and ci calculation were implemented in Python. For all of the other analyses, SPSS 23 software (IBM Corporation, Armonk, NY, USA) was used. In this study, two-sided tests were performed and *p*-values \< 0.05 were considered statistically significant.

Results {#s0040}
=======

In this retrospective study, the prognostic value of HPV16 DNA status, CSC markers and hypoxia classifiers presented in [@b0090] for 221 patients (training cohort) should be validated on an independent validation cohort of 152 patients. The patient data, treatment parameters and tumour characteristics of the training cohort have been described previously [@b0075], [@b0090]. They are summarised in [Table 1](#t0005){ref-type="table"} together with the values of the validation cohort and the comparison between both cohorts. Patients in the validation cohort were treated between 1999 and 2006 with PORT (*N* = 112) or PORT-C (*N* = 40), while all patients of the training cohort received PORT-C as the standard treatment (*p* \< 0.001). Furthermore, patients in the retrospective validation cohort had a significantly lower age (*p* = 0.016), delivered dose (*p* = 0.001), N stage (*p* \< 0.001), R status (*p* \< 0.001), extracapsular extension (ECE) status (*p* \< 0.001) and also showed a different distribution in their tumour localisations (*p* \< 0.001). The fraction of oropharyngeal tumours and tumours of the oral cavity were almost reverse in training and validation cohort (oropharynx: 57% vs 30%, oral cavity: 27% vs 55%). In the validation cohort HPV infection occurred less frequently than in the (more recently treated) training cohort (HPV16 DNA positivity: 14% vs. 33%, *p* \< 0.001). For the considered endpoints, patients in the validation cohort showed lower LRC and OS, while the occurrence of DM was not significantly different, see [Fig. 1](#f0005){ref-type="fig"}. Actuarial rates of LRC, freedom from DM and OS for the training and validation cohort were 90% vs 78% (*p* = 0.002), 85% vs 84% (*p* = 0.21) and 83% vs 68% (*p* \< 0.001), after two years, respectively.Fig. 1(A--C) Kaplan-Meier estimates of (A) loco-regional control (LRC), (B) freedom of distant metastases (DM) and (C) overall survival (OS) for the training and validation cohort.Table 1Comparison of the patient and tumour characteristics of the training and validation cohort.CharacteristicsTraining cohort\
(2004--2012)Validation cohort\
(1999--2006)*p*-ValueMedian (range)Median (range)Follow-up (months)46.2 (2.5--100.1)43.1 (1.8--153)0.29Age (years)57.0 (24.0--75.2)52.7 (36.3--71.0)**0.016**Dose (Gy)64 (56--68)64 (60--66)**0.001**Number of pts(%)Number of pts(%)Gender Male/Female180/41(81/19)127/25(84/16)0.60Clinical tumour (T) stage cT1/cT2/cT3/cT441/98/47/35(19/44/21/16)40/69/24/19(26/45/16/13)0.20Clinical nodal (N) stage cN0/cN1/cN2/cN322/31/138/30(10/14/62/14)15/31/104/2(10/20/68/1)**\<0.001**Stage (UICC 7th edition) I/II/III/IV0/8/33/180(0/4/15/81)2/3/34/113(1/2/23/74)0.069R status 0/1/unknown125/94/2(57/42/1)109/30/13(72/20/8)**\<0.001**ECE status 0/1/unknown103/118/0(47/53/0)104/47/1(68/31/1)**\<0.001**Localisation Oropharynx/oral cavity/hypopharynx/larynx126/60/35/0(57/27/16/0)46/83/15/8(30/55/10/5)**\<0.001**Grading 1/2/3/unknown5/123/89/4(2/56/40/2)3/78/71/0(2/51/47/0)0.55Chemotherapy yes/no221/0(100/0)40/112(26/74)**\<0.001**Smoking during therapy yes/no/unknown186/20/15(84/9/7)103/16/33(68/11/22)0.30Alcohol during therapy yes/no/unknown100/30/91(45/14/41)99/19/34(65/13/22)0.17p16 status negative/positive/unknown135/79/7(61/36/3)128/20/4(84/13/3)**\<0.001**HPV16 DNA status negative/positive/unknown143/72/6(65/33/2)126/22/4(83/14/3)**\<0.001**CD44 protein negative/positive/unknown44/151/26(20/68/12)15/130/7(10/85/5)**0.003***CD44* (log2-normalised expression) ⩽0.2 / \> 0.2 / unknown78/118/25(35/54/11)55/90/7(36/59/5)0.73*SLC3A2* (log2-normalised expression) ⩽−3.135 /\>−3.135 / unknown77/119/25(35/54/11)43/102/7(28/67/5)0.066*MET* (log2-normalised expression) ⩽−4.135 /\>−4.135 / unknown94/102/25(43/46/11)47/98/7(31/64/5)**\<0.001**15-gene hypoxia signature low hypoxic/highly hypoxic/unknown79/117/25(36/53/11)41/104/7(27/68/5)**0.021**26-gene hypoxia signature low hypoxic/highly hypoxic/unknown72/124/25(33/56/11)22/123/7(14/81/5)**\<0.001**Loco-regional recurrences29(13)38(25)**0.003**Distant metastases42(19)24(22)0.43Deaths70(32)86(57)**\<0.001**[^2]

[Table 2](#t0010){ref-type="table"} shows the results of univariate Cox regression with clinical parameters and HPV status for the considered endpoints of the validation cohort. Significantly lower LRC and OS was found for higher T stage (LRC: HR 2.46, *p* = 0.008; OS: HR 2.14, *p* = 0.001) and tumours of the oral cavity (LRC: HR 2.68, *p* = 0.005; OS: HR 2.22, *p* \< 0.001), while oropharyngeal tumours (LRC: HR 0.38, *p* = 0.020; OS: HR 0.40, *p* = 0.001) and HPV16 DNA positive tumours (LRC: HR 0.25, *p* = 0.060; OS: HR 0.35, *p* = 0.015) showed improved LRC and OS. These results are consistent with the findings of the training cohort [@b0090]. [Fig. 2](#f0010){ref-type="fig"} A-B shows Kaplan-Meier curves of the validation cohort stratified for HVP16 DNA status and use of chemotherapy. Patients with HPV16 DNA positive tumours showed significantly higher loco-regional control rates compared to patients with HPV16 DNA negative tumours using the Log-rank test; a statistical trend was obtained by Cox regression. The higher loco-regional control rates in the small patient group receiving PORT-C did not reach statistical significance.Fig. 2(A--I) Kaplan-Maier estimates of loco-regional control (LRC) for the validation cohort stratified for (A) HPV16 DNA status, (B) chemotherapy, (C--F) cancer stem cell (CSC) marker expression, (G and H) hypoxia-related gene classification and (I) combined risk. *Gene names are indicated using italics*.Table 2Univariate Cox regression with clinical variables as well as HPV status for the endpoints loco-regional control, freedom of distant metastases and overall survival for the validation cohort. Shown is the hazard ratio (HR) with 95% confidence interval (CI) and the *p*-value testing the hypothesis HR = 1.Loco-regional controlDistant metastasesOverall survivalVariableHR (95% CI)*p*-ValueHR (95% CI)*p*-ValueHR (95% CI)*p*-ValueAge (years)0.97 (0.94--1.01)0.16[⁎](#tblfn1){ref-type="table-fn"}0.99 (0.95--1.03)0.561.01 (0.99--1.04)0.31Dose (Gy)1.07 (0.94--1.24)0.311.21 (1.02--1.42)**0.022**1.07 (0.98--1.18)0.15Gender0.36 (0.11--1.16)0.0870.04 (0.00--1.33)0.0710.59 (0.31--1.15)0.12T stage (1,2 vs 3,4)2.46 (1.26--4.79)**0.008**[⁎](#tblfn1){ref-type="table-fn"}2.50 (1.24--5.05)**0.010**[⁎](#tblfn1){ref-type="table-fn"}2.14 (1.35--3.38)**0.001**[⁎](#tblfn1){ref-type="table-fn"}N stage (0,1 vs 2,3)0.87 (0.44--1.74)0.690.99 (0.47--2.09)0.98[⁎](#tblfn1){ref-type="table-fn"}0.85 (0.54--1.34)0.48UICC stage (I--III vs IV)1.13 (0.53--2.40)0.751.03 (0.48--2.21)0.950.99 (0.62--1.60)0.97R status0.86 (0.39--1.89)0.711.38 (0.64--3.00)0.411.29 (0.78--2.11)0.32ECE status1.60 (0.82--3.11)0.171.75 (0.87--3.49)0.11[⁎](#tblfn1){ref-type="table-fn"}1.41 (0.90--2.21)0.13[⁎](#tblfn1){ref-type="table-fn"}Oropharynx0.38 (0.17--0.86)**0.020**[⁎](#tblfn1){ref-type="table-fn"}0.41 (0.18--0.94)**0.034**[⁎](#tblfn1){ref-type="table-fn"}0.40 (0.23--0.68)**0.001**[⁎](#tblfn1){ref-type="table-fn"}Oral cavity2.68 (1.35--5.33)**0.005**[⁎](#tblfn1){ref-type="table-fn"}1.55 (0.78--3.08)0.21[⁎](#tblfn1){ref-type="table-fn"}2.22 (1.43--3.46)**\<0.001**[⁎](#tblfn1){ref-type="table-fn"}Hypopharynx0.91 (0.32--2.60)0.861.87 (0.77--4.53)0.170.89 (0.43--1.84)0.74Larynx0.40 (0.05--2.89)0.361.05 (0.31--3.59)0.941.02 (0.44--2.35)0.96Grading (1,2 vs 3)0.97 (0.50--1.86)0.921.81 (0.91--3.61)0.0941.12 (0.74--1.72)0.59Chemotherapy0.55 (0.23--1.32)0.181.42 (0.69--2.93)0.340.77 (0.45--1.31)0.33Smoking1.19 (0.36--3.98)0.782.20 (0.52--9.30)0.281.22 (0.55--2.68)0.63Alcohol0.87 (0.33--2.31)0.782.83 (0.67--12.0)0.161.26 (0.62--2.55)0.53p160.46 (0.14--1.49)0.19[⁎](#tblfn1){ref-type="table-fn"}0.46 (0.14--1.50)0.20[⁎](#tblfn1){ref-type="table-fn"}0.40 (0.17--0.92)**0.031**[⁎](#tblfn1){ref-type="table-fn"}HPV16 DNA0.25 (0.06--1.06)0.060[⁎](#tblfn1){ref-type="table-fn"}0.40 (0.12--1.33)0.13[⁎](#tblfn1){ref-type="table-fn"}0.35 (0.15--0.82)**0.015**[⁎](#tblfn1){ref-type="table-fn"}[^3][^4]

In [@b0090] a significant impact of the cancer stem-cell markers *CD44*, *SLC3A2* and *MET* on LRC was found using their expression values dichotomised at the cut-offs 0.2, −3.135 and −4.135, respectively. These cut-offs were used for patient stratification of the validation cohort. The resulting Kaplan-Meier curves are depicted in [Fig. 2](#f0010){ref-type="fig"}D--F. In univariate analyses, the impact of *CD44* (HR 2.14, *p* = 0.049) and *SLC3A2* (HR 2.45, *p* = 0.047) on LRC could be confirmed with lower hazard ratios, while *MET* expression showed no correlation with LRC ([Table 3](#t0015){ref-type="table"}). Also the significant impact of CD44 protein on LRC could be confirmed (*p* = 0.027, [Fig. 2](#f0010){ref-type="fig"}C). For the secondary endpoints only *CD44* showed a significant correlation with freedom of DM. The prognostic value of *MET* and *SLC3A2* for OS and DM could not be confirmed.Table 3Training (cohort 1) and validation (cohort 2) of univariate Cox models containing cancer stem cell marker expression or hypoxia classifiers for the endpoints loco-regional control, freedom of distant metastases and overall survival. Shown is the hazard ratio (HR) with 95% confidence interval (CI) and the *p*-value testing the hypothesis HR = 1.Loco-regional controlDistant metastasesOverall survivalHR (95% CI)*p*-ValueHR (95% CI)*p*-ValueHR (95% CI)*p*-ValueCohort*All patients*CD44 protein19.09 (1.24--66.8)**0.030**2.29 (0.90--5.86)0.0841.78 (0.91--3.50)0.0932[⁎](#tblfn2){ref-type="table-fn"}1.80 (0.43--7.54)0.421.16 (0.53--2.53)0.71*CD44* \> 0.213.56 (1.36--9.35)**0.010**1.69 (0.83--3.43)0.151.57 (0.92--2.67)0.09822.14 (1.00--4.56)**0.049**2.30 (1.04--5.08)**0.040**1.20 (0.76--1.89)0.44*SLC3A2* \> −3.13516.54 (1.97--21.7)**0.002**4.17 (1.74--10.0)**0.001**2.37 (1.36--4.13)**0.002**22.45 (1.01--5.91)**0.047**1.78 (0.77--4.10)0.181.19 (0.73--1.93)0.48*MET* \> −4.13515.19 (1.97--13.7)**0.001**3.41 (1.61--7.23)**0.001**2.74 (1.60--4.70)**\<0.001**21.43 (0.67--3.07)0.351.18 (0.56--2.47)0.670.93 (0.58--1.47)0.74  15-gene signature13.55 (1.35--9.35)**0.010**1.27 (0.65--2.46)0.491.47 (0.88--2.47)0.1422.32 (0.96--5.59)0.0611.06 (0.50--2.22)0.891.20 (0.74--1.96)0.4626-gene signature19.37 (2.22--39.5)**0.002**2.15 (1.01--4.55)**0.046**2.48 (1.39--4.42)**0.002**23.36 (0.81--14.0)0.0972.16 (0.66--7.07)0.211.26 (0.66--2.38)0.48  *Patients with HPV16 DNA-negative tumours*CD44 protein1[⁎](#tblfn2){ref-type="table-fn"}2.20 (0.53--9.18)0.281.45 (0.58--3.64)0.432[⁎](#tblfn2){ref-type="table-fn"}0.79 (0.19--3.35)0.750.68 (0.29--1.57)0.36*CD44* \> 0.214.15 (1.25--13.8)**0.020**1.69 (0.72--3.94)0.231.40 (0.76--2.58)0.2821.85 (0.86--3.96)0.112.54 (1.04--6.22)**0.041**1.17 (0.72--1.90)0.52*SLC3A2* \> −3.13519.23 (1.25--68.1)**0.029**3.56 (1.08--11.7)**0.037**1.53 (0.79--2.98)0.2121.87 (0.77--4.55)0.171.80 (0.69--4.73)0.231.13 (0.67--1.93)0.64*MET* \> −4.13513.74 (1.29--10.9)**0.015**2.82 (1.16--6.87)**0.023**2.42 (1.27--4.61)**0.007**20.97 (0.45--2.08)0.940.75 (0.34--1.66)0.480.71 (0.43--1.16)0.17  15-gene signature14.66 (1.60--13.5)**0.005**1.54 (0.73--3.21)0.261.88 (1.06--3.34)**0.031**22.13 (0.88--5.15)0.0931.37 (0.59--3.21)0.471.38 (0.80--2.37)0.2526-gene signature111.3 (1.53--83.7)**0.017**1.51 (0.65--3.51)0.342.05 (1.03--4.08)**0.040**21.62 (0.39--6.78)0.511.36 (0.32--5.73)0.680.91 (0.42--1.99)0.81[^5][^6]

For hypoxia-related gene classification based on the 15- and 26-gene signature [@b0080], [@b0085], k-means clustering was used in [@b0090]. Both classifiers were able to stratify patients into a group with high hypoxia-related gene expression and low LRC and a group with low hypoxia-related gene expression and better LRC. For the validation cohort, the hypoxia classification was performed using the cluster centres of the training cohort. Based on this classification, [Fig. 2](#f0010){ref-type="fig"}G and [2](#f0010){ref-type="fig"}H present Kaplan-Meier curves of tumours with low and high hypoxia-related gene expression for the validation cohort. A statistical trend for differences in LRC between both groups was obtained for both signatures (15-gene signature: HR 2.32, *p* = 0.061; 26-gene signature: HR 3.36, *p* = 0.097; [Table 3](#t0015){ref-type="table"}). Considering only patients with HPV16 DNA negative tumours, this trend remained for the 15-gene signature (HR 2.13, *p* = 0.093) but not for the 26-gene signature. In [@b0090] low-risk patients (HPV16 DNA positive or *SLC3A2* negative or low hypoxia) showed favourable LRC compared to the remaining high-risk patients. Here, this classification also yields a significant difference in LRC (*p* = 0.010, [Fig. 2](#f0010){ref-type="fig"}I).

In [@b0090] several multivariate Cox models were presented, which included HPV16 DNA status, one CSC marker and one hypoxia-associated gene classifier as well as the clinical parameters ECE status, tumour localisation oropharynx and hypopharynx. For the primary endpoint LRC, these models were applied to the validation cohort without adapting the model parameters. The prognostic performance of these models was then evaluated by the concordance index (ci). To reveal an additional impact of the CSC markers or hypoxia classifiers, the model performance was compared to a baseline model, which did not contain any CSC marker or hypoxia classifier. In [Table 4](#t0020){ref-type="table"} the results of the training cohort and the validation cohort are presented for all patients and for patients with HPV16 DNA negative tumours. For the training cohort, the baseline model showed a ci of 0.76 for all patients and of 0.66 for patients with HPV16 DNA negative tumours. Using additional CSC markers and hypoxia classifiers improved the ci up to 0.81 and 0.76, respectively, revealing their significant impact. For the validation cohort the baseline model showed ci = 0.66 for all patients and ci = 0.63 for patients with HVP16 DNA negative tumours. Including additional CSC markers or hypoxia classifiers improved these models only for *CD44* and the 15-gene hypoxia classifier up to ci = 0.69 and ci = 0.65, respectively. Validation on the patient subgroup which received PORT-C led to higher ci values for all CSC markers and hypoxia classifiers, however, due to the low patient number with large confidence intervals.Table 4Training and validation of multivariate Cox models for the endpoint loco-regional control containing cancer stem cell marker expression and hypoxia classifiers in addition to HPV16 DNA status and the clinical parameters ECE status, localisation oropharynx and hypopharynx. Shown is the concordance index (ci) with 95% confidence interval (CI) and the *p*-value testing the hypothesis ci = 0.5. Validation was also performed for the subgroup of patients who received radiochemotherapy (RCT).Training cohortValidation cohortValidation cohort, RCT onlyIncluded variablesci (95% CI)*p*-Valueci (95% CI)*p*-Valueci (95% CI)*p*-Value*All patients*Baseline (clinical parameters, HPV16 DNA status)0.76 (0.67--0.83)\<0.010.66 (0.58--0.75)\<0.010.69 (0.40--0.91)0.15*CD44* \> 0.20.76 (0.68--0.83)\<0.010.69 (0.60--0.77)\<0.010.77 (0.55--0.93)0.02*SLC3A2* \> −3.1350.77 (0.68--0.84)\<0.010.66 (0.56--0.76)\<0.010.72 (0.44--0.92)0.10*MET* \> −4.1350.78 (0.69--0.85)\<0.010.64 (0.54--0.74)0.010.75 (0.50--0.92)0.0415-gene signature0.80 (0.73--0.87)\<0.010.68 (0.58--0.77)\<0.010.74 (0.44--0.93)0.1026-gene signature0.79 (0.71--0.85)\<0.010.67 (0.58--0.75)\<0.010.71 (0.43--0.91)0.11*CD44* \> 0.2, 15-gene signature0.80 (0.72--0.87)\<0.010.69 (0.60--0.78)\<0.010.78 (0.53--0.94)0.04*SLC3A2* \> −3.135, 15-gene signature0.81 (0.73--0.87)\<0.010.67 (0.58--0.75)\<0.010.76 (0.48--0.95)0.07*MET* \> −4.135, 15-gene signature0.81 (0.74--0.88)\<0.010.66 (0.56--0.75)\<0.010.75 (0.47--0.93)0.07  *Patients with HPV16 DNA negative tumours*Baseline (clinical parameters)0.66 (0.55--0.77)0.010.63 (0.54--0.71)0.010.60 (0.21--0.87)0.49*CD44* \> 0.20.68 (0.58--0.77)\<0.010.63 (0.53--0.73)0.010.70 (0.41--0.90)0.13*SLC3A2* \> −3.1350.69 (0.58--0.79)\<0.010.62 (0.51--0.71)0.030.63 (0.26--0.89)0.38*MET* \> −4.1350.71 (0.60--0.81)\<0.010.58 (0.47--0.70)0.160.66 (0.31--0.90)0.2515-gene signature0.74 (0.65--0.82)\<0.010.64 (0.54--0.74)0.010.64 (0.25--0.91)0.3626-gene signature0.71 (0.62--0.80)\<0.010.62 (0.53--0.71)0.010.61 (0.26--0.88)0.42*CD44* \> 0.2, 15-gene signature0.74 (0.65--0.82)\<0.010.65 (0.54--0.74)0.010.69 (0.36--0.91)0.19*SLC3A2* \> −3.135, 15-gene signature0.76 (0.68--0.84)\<0.010.62 (0.52--0.72)0.030.68 (0.33--0.92)0.24*MET* \> −4.135, 15-gene signature0.76 (0.68--0.84)\<0.010.61 (0.50--0.71)0.050.66 (0.29--0.91)0.29

Discussion {#s0045}
==========

In our previous multicentre retrospective study, we showed that HPV status, tumour expression of CSC markers and hypoxia-related genes play a prognostic role in patients with locally advanced HNSCC, who were treated by PORT-C [@b0075], [@b0090]. In the current study, these results were validated on an earlier, independent cohort with patients who received PORT or PORT-C between 1999 and 2006. Despite significant differences in patient characteristics and treatment outcome between the two cohorts, the prognostic ability of the CSC markers CD44 protein, *CD44* and *SLC3A2* could be confirmed in univariate analyses; for the 15-gene hypoxia classifier a statistical trend was obtained. This underlines the robustness of the evaluated marker set. Furthermore, it could be shown that *CD44* and the 15-gene hypoxia classifier moderately improved the ci of the published multivariate Cox models. However, this improvement did not reach statistical significance.

The validation cohort consisted of patients treated between 1999 and 2006. These patients showed favourable clinical parameters with less R1-resected tumours and less lymphnodes showing extracapsular extension. However, LRC and OS were significantly lower compared to the later treated training cohort [@b0075]. This may be explained by the lower number of oropharyngeal cancers in this validation cohort, which show a significantly improved outcome due to a high radiosensitivity associated with positive HPV infection status [@b0105], [@b0110] and the higher number of tumours in the oral cavity that generally show poorer outcome. From the literature, there is also conflicting data on the value of HPV as a prognostic factor for non-oropharyngeal cancers. Lassen et al. showed that the radiotherapy outcome in the subgroup of non-oropharyngeal tumours does not differ by their p16 status [@b0060]. In contrast, Chung et al. demonstrated, that HPV infection may also play a role in a subset of non-oropharyngeal cancers [@b0115], suggesting that this needs further exploration. Furthermore, only 40 of the 152 patients received simultaneous radiochemotherapy since this had not been a standard treatment at that time. Technological advances in radiotherapy [@b0015] and diagnostics may also have contributed to a better outcome of the patients in the training cohort. Despite these significant differences a statistical trend for improved LRC for patients with HPV16 DNA positive tumours could be obtained, which is in agreement with our previous study [@b0075].

Validation of the multivariate Cox models published in [@b0090] showed a generally lower prognostic performance for the validation cohort than for the training cohort (training: ci 0.66--0.81, validation: ci 0.58--0.69). This difference is expected, as the models were adjusted to the training data. Furthermore, cut-offs for the continuous CSC marker expressions as well as the clustering procedure for hypoxia classification were optimised for the training cohort. However, with an average ci of 0.67 for the total validation cohort and of 0.62 for patients with HPV16 DNA negative tumours, the multivariate models were still prognostic with an acceptable performance. The large difference in ci between all patients and those patients with HPV16 DNA negative tumours shows that the HPV16 DNA status is a strong prognosticator for LRC. Still, *CD44* and the 15-gene hypoxia classifier were able to further improve the models, also in the validation cohort. At first glance, it is surprising that tumour hypoxia-associated gene expression of the resected tumour is associated with the outcome of postoperative radiotherapy. As discussed before [@b0090], it is very unlikely that the low number of any remaining tumour cells after surgery differs in their hypoxia status. However, this suggests that hypoxia may have the potential to impact the outcome after postoperative radiotherapy also by other radiobiological mechanisms than by direct biochemical or radiobiological effects. In previous data from our laboratory, it was shown that pre-treatment hypoxia has an impact on local tumour control after radiotherapy also when radiotherapy was applied under homogenous anoxic conditions [@b0120].

The prognostic ability of the putative CSC marker *MET* could not be confirmed by the validation cohort. However, the inclusion of *MET* resulted in multivariate models with higher ci values if only patients of the validation cohort who received PORT-C were considered. These models were not significant, which could be due to (1) the lower incidence of HPV positive tumours, which has shown to be associated with a lower CSC frequency [@b0125] and (2) the low number of patients receiving PORT-C in the validation cohort. Furthermore, in the validation cohort, patients only received PORT-C within clinical trials, i.e. a selection of patients with more favourable clinical characteristics is likely, leading to a more homogeneous patient group compared to the total cohort. In addition, diagnostics and radiotherapy treatment have been technologically improved over the last years, such that the consideration of biological aspects might become even more important.

It should be noted that in the previously reported DKTK-ROG cohort [@b0090] *CD44* expression was determined by real-time PCR (RT-PCR) analysis because the nanoString *CD44* probe design was invalid. In the present validation cohort, *CD44* expression was measured by valid nanoString probes. Therefore, the validation of *CD44* is challenging, as its expression in the two cohorts was determined by different methods and the cut-off value 0.2 obtained for RT-PCR might be different for nanoString. In general, many genes of the validation cohort showed significantly different mean expression values between the cohorts, i.e. an average shift. This is problematic if the expressions are dichotomized at cut-off values, as these cut-offs may lead to imbalanced patient groups for the validation cohort. The same holds for the hypoxia classifiers built by k-means clustering. In the validation cohort, this shift in gene expressions caused the hypoxia classifiers to identify significantly more hypoxic tumours compared to the training cohort. Renormalizing the validation data to the training data, as described in [@b0130], gives the same fraction of more and less hypoxic tumours for both cohorts and even leads to a significant impact of hypoxia status on LRC, in contrast to the statistical trend shown in [Table 3](#t0015){ref-type="table"}. However, this method is not applicable for individual patient prognosis, as required in clinical trials on treatment adaptation, and may warrant the inclusion of reference samples in future analyses.

The model validation showed a better performance for the subgroup of patients, which received PORT-C than for all patients. This indicates that the prognostic ability of CSC markers and hypoxia classifiers might be stronger for a patient cohort, which is more similar to the cohort originally used in [@b0090]. However, at the time of treatment of the validation cohort simultaneous radiochemotherapy was applied only within clinical studies [@b0035], [@b0040], [@b0045]. This potentially led to a higher homogeneity with better clinical performance of the patient subgroup treated with PORT-C, which is important for the interpretation of the biological heterogeneity of the tumours. Currently, a homogeneous patient cohort with locally advanced HNSCC treated with PORT-C is being recruited within a prospective clinical trial of the DKTK-ROG, which will allow for further validation of the models.

Taken together, this validation study confirmed the prognostic value of the HPV infection status, CSC marker expression of CD44 protein, *CD44* and *SLC3A2* and tumour hypoxia status presented in [@b0090] for patients with locally advanced HNSCC receiving postoperative radiotherapy or radiochemotherapy. While a lower performance of the prognostic models is expected due to the older validation dataset and several differences between the cohorts, the significant validation results indicate the robustness of these biomarkers. After further validation on a currently recruiting prospective clinical trial of the DKTK-ROG these models may help to stratify patients for individualised treatment de-escalation or intensification strategies.
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